β2-AR inhibition enhances EGFR antibody efficacy hampering the oxidative stress response machinery
Open Access
- 19 September 2023
- journal article
- research article
- Published by Springer Nature in Cell Death & Disease
- Vol. 14 (9) , 1-10
Abstract
The β2-Adrenergic receptor (β2-ARs) is a cell membrane-spanning G protein-coupled receptors (GPCRs) physiologically involved in stress-related response. In many cancers, the β2-ARs signaling drives the tumor development and transformation, also promoting the resistance to the treatments. In HNSCC cell lines, the β2-AR selective inhibition synergistically amplifies the cytotoxic effect of the MEK 1/2 by affecting the p38/NF-kB oncogenic pathway and contemporary reducing the NRF-2 mediated antioxidant cell response. In this study, we aimed to validate the anti-tumor effect of β2-AR blockade and the synergism with MEK/ERK and EGFR pathway inhibition in a pre-clinical orthotopic mouse model of HNSCC. Interestingly, we found a strong β2-ARs expression in the tumors that were significantly reduced after prolonged treatment with β2-Ars inhibitor (ICI) and EGFR mAb Cetuximab (CTX) in combination. The β2-ARs down-regulation correlated in mice with a significant tumor growth delay, together with the MAPK signaling switch-off caused by the blockade of the MEK/ERK phosphorylation. We also demonstrated that the administration of ICI and CTX in combination unbalanced the cell ROS homeostasis by blocking the NRF-2 nuclear translocation with the relative down-regulation of the antioxidant enzyme expression. Our findings highlighted for the first time, in a pre-clinical in vivo model, the efficacy of the β2-ARs inhibition in the treatment of the HNSCC, remarkably in combination with CTX, which is the standard of care for unresectable HNSCC.Keywords
This publication has 54 references indexed in Scilit:
- Molecular Pathways: Beta-Adrenergic Signaling in CancerClinical Cancer Research, 2012
- A stress response pathway regulates DNA damage through β2-adrenoreceptors and β-arrestin-1Nature, 2011
- Beta-Blocker Use Is Associated With Improved Relapse-Free Survival in Patients With Triple-Negative Breast CancerJournal of Clinical Oncology, 2011
- Erlotinib-Mediated Inhibition of EGFR Signaling Induces Metabolic Oxidative Stress through NOX4Cancer Research, 2011
- Agonist-Directed Desensitization of the β2-Adrenergic ReceptorPLOS ONE, 2011
- Stress Effects on FosB- and Interleukin-8 (IL8)-driven Ovarian Cancer Growth and MetastasisJournal of Biological Chemistry, 2010
- Adrenergic modulation of focal adhesion kinase protects human ovarian cancer cells from anoikisJournal of Clinical Investigation, 2010
- A Versatile Viral System for Expression and Depletion of Proteins in Mammalian CellsPLOS ONE, 2009
- Proteomic Signatures of Epidermal Growth Factor Receptor and Survival Signal Pathways Correspond to Gefitinib Sensitivity in Head and Neck CancerClinical Cancer Research, 2009
- The influence of bio-behavioural factors on tumour biology: pathways and mechanismsNature Reviews Cancer, 2006